JOHNSON & JOHNSON Q4 2024 Filing

Filed February 13, 2025

Portfolio Value

$386.1B

Holdings

20

Report Date

Q4 2024

Filing Type

13F-HR

All Holdings (20 positions)

#StockSharesValue% PortfolioType
1
PTGXProtagonist Therapeutics Inc.
2,449,183$94.5B24.48%
2
CVRXCVRx, Inc.
4,103,430$52.0B13.46%
3
RAPPRapport Therapeutics, Inc.
2,498,051$44.3B11.48%
4
MGTXMeiraGTx Holdings plc
6,641,064$40.4B10.47%
5
CTNMContineum Therapeutics Inc.
1,979,173$29.0B7.51%
6
PRCTProcept BioRobotics Corporation
357,939$28.8B7.46%
7
LEGNLegend Biotech Corporation
814,586$26.5B6.86%
8
NMRANeumora Therapeutics, Inc.
1,849,445$19.6B5.08%
9
XNCRXencor, Inc.
748,062$17.2B4.45%
10
NBTXNanobiotix S.A.
5,623,816$16.1B4.18%
11
FATEFate Therapeutics, Inc.
3,379,064$5.6B1.44%
12
ARWRArrowhead Pharmaceuticals, Inc.
247,598$4.7B1.21%
13
RLYBRallybio Corporation
3,636,363$3.5B0.90%
14
VORVor Biopharma, Inc.
1,074,658$1.2B0.31%
15
NNOXNano-X Imaging Ltd.
158,852$1.1B0.30%
16
FLBStandard BioTools Inc
311,967$545.9M0.14%
17
LYELLyell Immunopharma Inc.
823,317$526.9M0.14%
18
TORCEURAdicet Bio, Inc.
364,472$350.6M0.09%
19
PHGEBiomX Inc.
96,866$70.7M0.02%
20
SENS1GBPSenseonics Holdings, Inc.
54,621$28.6M0.01%